Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional IL-2 for Suspicious Pigmented Skin Lesions
NCT03233828Phase 3Terminated
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aldesleukin in melanoma. Primary endpoints: Assessment of Number of Patients Needed to Obtain Significance at 1 year and Assessment of Metastasis at 5 years. Started Oct 2019; status: terminated.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03233828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233828.